Security
ABPRO HLDGS INC Warrant 11/12/2029 · ABPWW
ABPWWOTCWarrantCurrentCIK 1893219Updated Nov 15, 2026
Name history
Atlantic Coastal Acquisition Corp. II · through Nov 12, 2024
ABPWW price & chart
Loading TradingView…
OTC:ABPWW on TradingView ↗About the company
Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using Abpro’s proprietary DiversImmune® platform. Abpro is located in Burlington, Massachusetts. For more information, please visit www.abpro.co.
In the news
No coverage from other publishers is available.
Recent filings
25-NSE - filed by Nasdaq Stock Market LLC regarding Abpro Holdings, Inc.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
10-Q filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,703,000Source | 7,858,053Source | 5,241,000Source | 3,483,000Source | 7,896,323Source | 6,865,000Source | 2,797,000Source | 7,533,844Source | 1,063,000Source | 4,661,000Source | 37,365,979Source | 310,560,681Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 27,000Source | — | — | 31,000Source | — | — | 37,000Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 13,597Source | — | — | 236,779Source | — | — | 10,613Source | — | 2,850,000Source | 264,538Source | 392,446Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 271,000Source | — | — | 342,000Source | — | 183,000Source | 331,000Source | — | 183,000Source | 323,000Source | — | — |
| Assets, CurrentUSD | 1,225,000Source | 1,560,441Source | 5,079,000Source | 3,068,000Source | 277,279Source | 6,701,000Source | 2,219,000Source | 25,756Source | 896,000Source | 3,776,000Source | 29,993,528Source | 770,226Source |
| Prepaid Expense and Other Assets, CurrentUSD | 611,000Source | — | 788,000Source | 697,000Source | — | 1,050,000Source | 483,000Source | — | 480,000Source | 306,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | 137,000Source | — | — | 275,000Source | — | — | 418,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | 19,541,035Source | — | — | 17,806,375Source | — | — | 17,105,045Source | — | 19,607,000Source | 45,888,457Source | 12,642,163Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | 0Source | — | — | 0Source | — | — | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | — | — | 1,000Source | 7,000Source | — | 1,000Source | 5,000Source | — | — | 5,000Source | — | — |
| Additional Paid in CapitalUSD | 108,487,000Source | — | 117,429,000Source | 105,471,000Source | 0Source | 117,221,000Source | 101,625,000Source | 0Source | 110,164,000Source | 100,603,000Source | 0Source | — |
| Retained Earnings (Accumulated Deficit)USD | -124,631,000Source | -17,811,367Source | -120,963,000Source | -122,974,000Source | -17,398,123Source | -120,023,000Source | -119,990,000Source | -16,985,789Source | -118,995,000Source | -116,103,000Source | -15,815,868Source | -11,180,162Source |
| Stockholders' Equity Attributable to ParentUSD | -16,144,000Source | -17,810,617Source | -3,533,000Source | -17,496,000Source | -17,397,373Source | -2,801,000Source | -18,360,000Source | -16,985,039Source | -8,831,000Source | -15,495,000Source | -15,815,118Source | -11,179,412Source |
| Liabilities and EquityUSD | 1,703,000Source | 7,858,053Source | 5,241,000Source | 3,483,000Source | 7,896,323Source | 6,865,000Source | 2,797,000Source | 7,533,844Source | 1,063,000Source | 4,661,000Source | 37,365,979Source | 310,560,681Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 17,298,000Source | 9,041,035Source | 8,225,000Source | 20,430,000Source | 7,306,375Source | 9,117,000Source | 20,608,000Source | 6,605,045Source | 9,345,000Source | 19,607,000Source | 35,388,456Source | 2,142,163Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | 149,000Source | — | — | 300,000Source | — | — | 456,000Source | — | — |
| Accounts Payable, CurrentUSD | 4,724,000Source | — | 4,159,000Source | 5,266,000Source | — | 4,952,000Source | 4,704,000Source | — | 5,323,000Source | 3,936,000Source | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 549,000Source | — | 549,000Source | 549,000Source | — | 549,000Source | 549,000Source | — | 549,000Source | 549,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 8,026,000Source | — | 3,895,000Source | 8,020,000Source | — | 3,871,000Source | 7,778,000Source | — | 3,875,000Source | 7,496,000Source | 469,268Source | 1,243,172Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -1,657,000Source | -2,093,000Source | -940,000Source | -2,984,000Source | -1,028,000Source | -3,887,000Source | -2,892,000Source | -7,232,000Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 3,000Source | 8,000Source | 21,000Source | 74,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 302,000Source | 512,000Source | 1,489,000Source | 1,927,000Source | 0Source | 362,500Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | 8,000Source | — | 235,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -371,000Source | 768,000Source | 1,247,000Source | -860,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,080,000Source | -1,503,000Source | -6,006,000Source | -9,030,000Source | -3,845,177Source | -1,184,963Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 278,443,729Source | -305,668,484Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 276,471,460Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,411,000Source | -84,000Source | 3,070,000Source | 11,161,000Source | -274,726,460Source | 307,245,893Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | -127,908Source | 392,446Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 343,000Source | 141,000Source | 4,236,000Source | 2,029,000Source | 5,413,000Source | 1,405,000Source | 82,000Source | 2,992,000Source | 264,538Source | 392,446Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 21,000Source | 1,000Source | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | 1,799,627Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 286,000Source | 415,000Source | 208,000Source | 360,000Source | 302,000Source | 512,000Source | 1,489,000Source | 1,927,000Source | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | 76,000Source | 160,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | 3,000Source | — | 6,000Source | 11,000Source | 65,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 200,000Source | 173,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,093,000Source | 1,472,000Source | 1,166,000Source | 1,948,000Source | 920,000Source | 2,633,000Source | 7,463,000Source | 7,121,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | 27,654Source | — | — | — | — | — | — | 1,177,463Source | 823,991Source |
| InterestExpenseNonoperatingUSD | — | — | 193,000Source | 164,000Source | 23,000Source | 174,000Source | 23,000Source | 737,000Source | 1,128,000Source | 387,000Source | — | — |
| Investment Income, InterestUSD | — | — | 6,000Source | 2,000Source | 39,000Source | 6,000Source | 22,000Source | 18,000Source | 33,000Source | 9,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -335,100Source | — | — | — | -3,887,000Source | — | — | 2,821,459Source | 886,918Source |
| Nonoperating Income (Expense)USD | — | — | -321,000Source | -162,000Source | 235,000Source | -723,000Source | -95,000Source | -929,000Source | 5,560,000Source | 2,689,000Source | 5,664,978Source | 3,761,319Source |
| Operating ExpensesUSD | — | — | 1,336,000Source | 2,114,000Source | 1,175,000Source | 2,261,000Source | 933,000Source | 2,958,000Source | 8,452,000Source | 10,104,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 13,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 132,000Source | 132,000Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -362,500Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Noncash Merger Related Costs | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Operating Costs and Expenses | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | 183,000Source | — | — |
| Operating Income (Loss)USD | — | — | -1,336,000Source | -1,931,000Source | -1,175,000Source | -2,261,000Source | -933,000Source | -2,958,000Source | -8,452,000Source | -9,921,000Source | -1,666,056Source | -2,050,410Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -307,446Source | — | — | — | — | — | -7,232,000Source | 3,998,922Source | 1,710,909Source |
| Income Tax Expense (Benefit)USD | — | — | — | 27,654Source | — | — | — | — | — | — | 1,177,463Source | 823,991Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | -335,100Source | — | — | — | -3,887,000Source | — | — | 2,821,459Source | 886,918Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.63Source | -3.27Source | -0.16Source | -1.56Source | -0.23Source | -2.29Source | -1.3Source | -0.74Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.63Source | -3.27Source | -0.16Source | -1.56Source | -0.23Source | -2.29Source | -1.3Source | -0.74Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 2,613,889Source | 640,606Source | 5,896,048Source | 1,917,246Source | 4,490,505Source | 1,697,414Source | 2,232,610Source | 23,409,969Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 2,613,889Source | 640,606Source | 5,896,048Source | 1,917,246Source | 4,490,505Source | 1,697,414Source | 2,232,610Source | 23,409,969Source | — | — |
| Interest Expense (non-operating)USD | — | — | 193,000Source | 164,000Source | 23,000Source | 174,000Source | 23,000Source | 737,000Source | 1,128,000Source | 387,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 3,000Source | 8,000Source | 21,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,093,000Source | 1,472,000Source | 1,166,000Source | 1,948,000Source | 920,000Source | 2,633,000Source | 7,463,000Source | 7,121,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | — | -7,232,000Source | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | 52,304Source | 1,848Source |
| Investment Income, InterestUSD | — | — | 6,000Source | 2,000Source | 39,000Source | 6,000Source | 22,000Source | 18,000Source | 33,000Source | 9,000Source | — | — |
| Net Income (Loss) from Continuing Operations Available to Common Shareholders, BasicUSD | — | — | — | — | — | — | — | — | -2,892,000Source | -17,409,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -321,000Source | -162,000Source | 235,000Source | -723,000Source | -95,000Source | -929,000Source | 5,560,000Source | 2,689,000Source | 5,664,978Source | 3,761,319Source |
| Operating ExpensesUSD | — | — | 1,336,000Source | 2,114,000Source | 1,175,000Source | 2,261,000Source | 933,000Source | 2,958,000Source | 8,452,000Source | 10,104,000Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 13,000Source | — | — | — |
| Other IncomeUSD | — | — | — | — | — | — | 2,000Source | — | — | 3,556,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 243,000Source | 642,000Source | 9,000Source | 313,000Source | 13,000Source | 325,000Source | 989,000Source | 2,983,000Source | — | — |
| Interest Expense | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Operating Costs and Expenses | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Other Expenses | — | — | —Source | — | — | — | — | — | — | — | — | — |
Filing attachments
ea027184401ex99-1_abpro.htm · 8-K · 2026-01-06
Exhibit 99.1 Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro’s global collaboration with Celltrion BURLINGTON, Mass. and INCHEON, South Korea - January 6, 2026 - Abpro Holdings, Inc. (Nasdaq: ABP), a biotechnology company developing next-generation antibod…
Read attachment ↗